Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus bevacizumab with carboplatin-paclitaxel or pemetrexed in EGFR-mutated NSCLC
2019-001687-30Phase 2Completed
- Sponsor
- European Thoracic Oncology Platform
- Start
- Mar 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing Tecentriq + Avastin + carboplatin + paclitaxel with Tecentriq + Avastin + carboplatin + pemetrexed (2 arms). Primary endpoint: Progression-free survival rate at 12 months. Started Mar 2020; status: completed.
02
Drugs
atezolizumabbevacizumabcarboplatinpaclitaxelpemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2019-001687-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001687-30.